Week in Review: Yuanxin Raises $465 Million for Online Healthcare Company Miaoshou Doctor

Deals and Financings   Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations known as Miaoshou Doctor; Shanghai Microport Cardioflow, a spinout from China device maker Microport , staged a $324 million Hong Kong IPO for its transcatheter aortic valve implants; Qilu Pharma of Jinan formed a $235 million collaboration with San Diego 's Cend Therapeutics to develop and commercialize Cend’s immunotherapy in China ; Hangzhou Zhongmei Huadong Pharma signed a $180 million agreement with Provention Bio of New Jersey to develop a bispecific autoimmune drug; Beijing 's BeiGene in-licensed China rights to novel TNF receptor antibodies from Boston Immune Technologies and Therapeutics in a $126 million agreement; Regor Therapeutics of Shanghai completed a $90 million Series B financing to develop novel medicines for cancer, immune disorders and metabolic diseases; Hangzhou Sciwind closed a $37 million series B financing for therapies that treat metabolic and immunological diseases; Citrine Medicine, a Shanghai rare disease company, in-licensed China rights to an adrenal hormone replacement therapy developed by the UK's Diurnal Group; Hansoh Pharma of Jiangsu Province acquired China rights to a Synexis anti-fungal candidate for difficult-to-treat infections; Trials and Approvals   China Oncology Focus (COF), a Lee's Pharma subsidiary, reported that its anti-PD-L1 antibody was granted breakthrough therapy status in China . Stock Symbols: (HK: 2160) (HK: 0853) (NSDQ: PRVB) (NSDQ: BGNE; HK: 06160)  (AIM: DNL) (HK: 3692) (NSDQ: SCYX) (HK: 950) Share this with colleagues: // //